LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company, announced today that it expects to formally submit a corporate action request to FINRA seeking approval of a proposed five-for-one forward stock split, along with proportional increases in authorized common and preferred stock. The move is intended to support broader long-term operational scalability, strategic flexibility, and future growth initiatives as the company continues advancing telehealth infrastructure in Latin America and other emerging markets.
The proposed forward stock split would apply proportionally to all issued and outstanding shares of common stock and outstanding preferred stock designations, including the Series C Voting Preferred Stock. The company emphasized that the action does not involve debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected to be issued; any fractional interests would be rounded up to the nearest whole share.
Management stated that the forward stock split forms part of a broader effort to align the company's capital structure with its transition into digital healthcare infrastructure and artificial intelligence-driven telehealth operations. Dr. Kevin Rodan Levy, Chief Executive Officer, commented, "As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives."
The company recently commenced initial operational activities for its telehealth platform in Venezuela after receiving regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This regulatory progression marks a significant step in the company's strategy to deploy scalable healthcare solutions in emerging markets.
The proposed forward stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. The company noted that no assurance can be provided regarding the timing or ultimate effectiveness of the action.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
